



04

Our Profile

Eiken Chemical's Businesses	54
Main Products and Services	55
Financial Highlights	56
Non-Financial Highlights	57
External Evaluation/Stock Information, Etc.	58

Eiken Chemical's Businesses


Overview of business

Manufacture and sale of pharmaceuticals, reagents, and medical, physical, and chemical machinery and equipment, as well as the import and export for sale of the same. Our products are a familiar part of life for everybody from babies to senior citizens.

Business domains

Clinical diagnostics

Clinical diagnostics are a kind of test used in diagnosis, treatment, and screening of disease, and can be categorized into laboratory tests and physiological function tests. As a comprehensive manufacturer of clinical diagnostics, Eiken Chemical responds to the needs of the most advanced medicine through the R&D, manufacturing and sales of products and services that cover a wide range of laboratory tests.



Testing of food and environment

Eiken Chemical manufactures and sells reagents of microbiological tests for food poisoning bacteria and for environmental inspection to measure contamination of work environments, and sells testing tools and devices.

Clinical diagnostics market

Domestic market

¥**933.3** billion
(FY2023; source:
survey by the Japan Association
of Clinical Reagents Industries)

Annual
growth of
2%
forecast

The clinical diagnostics market in Japan was valued at ¥817.9 billion (83% of previous year), shrinking due to lower sales of COVID-19-related reagents. Including exports, the market was valued at approximately ¥933.3 billion (89% of previous year). Revisions to medical treatment fees in 2024 resulted in a reduction in drug prices of 0.97%, but the impact was minor. Over the medium term, the Japanese market is forecast to trend gently upwards at an annual rate of about 2%.


Global market

US\$**78.7** billion
(2023)
(Report Code: MD3609)

Annual growth
of approx.
6.9%
forecast
(average 2024-2029)


The global market for clinical diagnostics was estimated to be US\$78.7 billion in 2023, and is forecast to grow at a compound annual growth rate of 6.9%. Factors cited as driving the market include increases in chronic conditions and infectious diseases resulting from the increase in elderly individuals and, in terms of market opportunities, the growth of developing markets.

Business model



Main Products and Services

As a comprehensive manufacturer of clinical diagnostics, the Eiken Group offers a broad lineup of products and services.



Financial Highlights

		FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Net sales	Million yen	34,991	35,761	36,585	38,667	42,996	43,271	40,052	40,539
of which overseas sales	Million yen	5,405	6,070	7,040	6,895	8,868	8,797	10,115	10,710
Gross profit	Million yen	14,701	15,692	16,229	18,529	20,564	20,506	16,723	16,512
Operating profit	Million yen	3,478	4,611	4,622	6,612	8,387	7,457	3,377	2,999
Ordinary profit	Million yen	3,549	4,681	4,723	6,808	8,508	7,568	3,568	3,198
Net profit attributable to owners of parent	Million yen	2,608	3,447	3,538	5,044	6,218	5,736	2,634	2,228
Total assets	Million yen	45,165	47,279	50,322	55,685	62,512	66,275	61,651	62,372
Net assets	Million yen	32,478	35,014	37,303	41,672	45,803	49,535	45,971	43,598
EBITDA	Million yen	5,138	6,205	6,249	8,323	10,445	9,582	5,703	5,532
R&D expenses	Million yen	3,238	2,904	3,332	3,086	3,408	4,065	3,939	4,386
Capital investment	Million yen	1,102	1,685	2,985	2,876	4,347	3,792	1,812	7,699
Depreciation	Million yen	1,660	1,594	1,627	1,711	2,058	2,125	2,326	2,533
Net cash	Million yen	8,597	6,356	8,893	8,071	11,930	14,062	11,973	5,407
Cash flows from operating activities	Million yen	4,091	3,318	5,460	5,451	7,769	7,575	3,806	6,033
Cash flows from investing activities	Million yen	(3,250)	(4,435)	(3,711)	(2,193)	(5,044)	(316)	(2,216)	(4,499)
Cash flows from financing activities	Million yen	(1,175)	(1,083)	(1,220)	(1,275)	1,200	(2,095)	(6,694)	(4,857)
Cash and cash equivalents at end of period	Million yen	6,651	4,448	4,981	6,968	10,900	16,064	10,966	7,640
Operating profit to net sales ratio	%	9.94	12.89	12.63	17.1	19.5	17.2	8.4	7.4
Return on Equity (ROE)	%	8.3	10.3	9.9	12.9	14.3	12.1	5.6	5.0
Return on Assets (ROA)	%	5.8	7.5	7.3	9.5	10.5	8.9	4.1	5.2
Equity ratio	%	71.2	73.5	73.5	74.3	72.8	74.2	74.0	69.3
Earnings per share (EPS)	Yen	71.21	93.63	95.95	136.65	168.28	155.17	71.69	64.82
Book value per share (BPS)	Yen	877.35	942.37	1,002.86	1,120.36	1,230.55	1,327.47	1,318.38	1,294.08
Dividend payout ratio (consolidated)	%	35.1	32.0	31.3	30.0	30.3	32.9	71.1	81.8
Dividend per share	Yen	25.00	30.00	30.00	41.00	51.00	51.00	51.00	53.00
Total number of issued shares at end of period	Shares	43,541,438	43,541,438	43,541,438	43,541,438	43,541,438	43,541,438	40,041,438	38,541,438
Number of treasury shares at end of period	Shares	6,902,222	6,659,650	6,659,760	6,611,071	6,576,861	6,512,625	5,443,508	5,127,632
Market capitalization	Billion yen	116.6	113.4	85.8	94.1	75.1	68.0	80.0	87.3
Number of employees at end of period (full-time employees)	Persons	704	719	724	733	745	754	757	702

*The Company conducted a two-for-one share split of its common shares with an effective date of April 1, 2018.
Figures for EPS, BPS, and dividend per share for FY2017 are calculated based on the assumption that the share split was conducted on April 1, 2017.

Non-Financial Highlights

			FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024
Environment	Greenhouse gas (GHG) emissions ◆1									
	Scope 1	t-CO ₂	2,120	1,989	1,934	2,070	2,016	1,945	2,036	1,971
	Scope 2	t-CO ₂	5,252	5,181	4,884	5,038	5,304	2,669	706	678
	Scope 3 *1	t-CO ₂	–	–	–	86,485	105,335	84,205	71,698	77,708
	Renewable energy used ◆4	MWh	70	76	70	61	62	6,871	11,764	11,548
	Water volume consumed ◆2	1,000 m ³	88.1	83.9	81.0	78.1	80.7	73.1	68.7	69.1
	Total waste generated ◆3 *2	t	426	381	388	410	462	529	398	415
	Material recycled ◆3	t	251	212	234	223	232	247	238	227
	Recycling ratio (including recovered energy) ◆3	%	58.9	55.7	68.0	62.4	58.8	55.3	62	64
Society ◆4	Number of ecological proposals ◆4	Proposals	366	445	454	318	291	518	525	567
	Average age (Overall)	Years	43 years 0 months	42 years 7 months	42 years 6 months	42 years 4 months	42 years 3 months	42 years 5 months	42 years 5 months	41 years 5 months
	Average age (Men)	Years	44 years 0 months	43 years 5 months	43 years 2 months	42 years 10 months	42 years 7 months	42 years 5 months	42 years 1 month	41 years 8 months
	(Women)	Years	40 years 7 months	40 years 5 months	41 years 0 months	41 years 1 month	41 years 5 months	42 years 4 months	42 years 1 month	41 years 7 months
	Average years of service (Men)	Years	16 years 11 months	16 years 2 months	14 years 11 months	16 years 2 months	15 years 7 months	15 years 7 months	14 years 10 months	14 years 2 months
	(Women)	Years	16 years 0 months	16 years 1 month	16 years 6 months	16 years 9 months	16 years 10 months	17 years 7 months	16 years 10 months	15 years 11 months
	Female employees as share of total	%	27.3	29.0	29.4	29.7	30.3	29.2	29.9	30.3
	Female managers as share of managers (as of April each year) *3	%	10.7	12.2	14.6	16.9	16.2	13.8	15.4	18.8
	Female Directors as share of Directors	%	0.0	11.0	11.0	11.0	11.0	13.0	13.0	20.0*8
	Proportion of women among new hires	%	29.2	35.6	20.0	27.5	29.3	17.5	36.4	39.0
	Percentage returning to work after childcare leave	%	100	100	100	100	100	100	100	100
	Employee turnover *4	%	0.9	0.9	2.0	1.7	2.0	2.7	2.3	1.9
	Average non-scheduled working hours per full-time employee per month	Hours	–	14.1	15.8	16.2	15.3	14.8	13.9	12.8
Governance	Rate of uptake of EIKEN GLOBAL PROGRAM among employees *5	%	–	–	–	16.5	14.0	19.4	26.3	27.2
	Employee satisfaction score *6	–	–	–	–	–	–	68.6	62.1	58.8
	Rate of uptake of antibribery training	%	–	–	–	–	96.8	100.0	100	100
	Number of serious noncompliance incidents *7	Cases	0	0	0	0	0	0	0	0

Scope 1 GHG emissions: GHG emitted directly from company facilities, plants, and vehicles

Scope 2 GHG emissions: GHG emitted indirectly by the company as a result of energy usage

Scope 3 GHG emissions: GHG emitted by the entire cluster of companies involved in a product or service (supply chain)

<Applicable scope>

◆1 Eiken Group: EIKEN CHEMICAL, EIKEN CHINA CO., LTD.

◆2 Eiken Group (production sites)

◆3 Eiken Group (headquarters/production sites/research facilities)

◆4 EIKEN CHEMICAL only

*1 The Company calculates items within the scope in accordance with Scope 3 items based on the GHG protocol

*2 Total waste generated = general waste + industrial waste

*3 Managerial position: a post of section chief or higher

*4 Numerator = number of full-time employees leaving between April 1 of each year and March 31 of the following year
Denominator = calculated as number of full-time employees on April 1 each year

*5 Rate of uptake of EIKEN GLOBAL PROGRAM = number of those attending training each fiscal year ÷ number of employees for each fiscal year

*6 Calculated based on the number of positive responses received in the employee satisfaction survey with a five-grade scale

*7 The total of material infringements of a country's competition laws, material infringements of the laws and regulations related to corruption, and material infringements in socioeconomic areas other than these

*8 As of June 2025

External Evaluation/Stock Information, Etc.

External evaluation

Inclusion in ESG indices



**FTSE Blossom
Japan Index**



**FTSE Blossom
Japan Sector
Relative Index**



MORNINGSTAR GenDi J
Japan ex-REIT Gender Diversity
Tilt Index

Initiatives endorsed/ESG ratings/certifications



Signed high-level Kigali Declaration on elimination of neglected tropical diseases (NTDs)



Sponsor of international public-private sector GHIT Fund to fight infectious diseases



Endorsed TCFD recommendations and made disclosure in February 2023



Gained SBT certification in February 2024



Climate Change Corporate A List



Synergy A Rating



Certified for 6 consecutive years



Certified as Organization Contributing to National Resilience by Cabinet Secretariat National Resilience Promotion Office



Participation in Triple I

Company profile

Company name	EIKEN CHEMICAL CO., LTD.
Head office location	4-19-9 Taito, Taito-ku, Tokyo, 110-8408 Japan (as of August 31, 2025) <small>*The Company plans to move to a new Head Office in September 2025.</small>
New address	20th floor, Ochanomizu sola city, 4-6 Kanda-Surugadai, Chiyoda-ku, Tokyo, 101-0062 Japan
Representative	Yuji Segawa, President and CEO
Founded	February 20, 1939
Share capital	6,897,730,000 yen (as of March 31, 2025)

Number of employees (full-time employees + temporary employees)	Non-consolidated: 1,047; Consolidated 1,051 (as of March 31, 2025)
Listed stock exchange	Tokyo Stock Exchange Prime Market
Securities code	4549
Year-end	March 31
Annual General Meeting of Shareholders	June of each year

Shares information (as of March 31, 2025)


Total number of shares authorized to be issued	123,900,000 shares
Total number of issued shares (including treasury shares)	38,541,438 shares
Number of shares per unit	100 shares
Number of shareholders	5,732

Major shareholders

Shareholder name	Number of shares held (shares)	Shareholding ratio (%)
The Master Trust Bank of Japan, Ltd. (Trust account)	5,089,100	15.23
NIPPON ACTIVE VALUE FUND PLC	3,228,600	9.66
STATE STREET BANK AND TRUST COMPANY 505103	2,009,759	6.01
Custody Bank of Japan, Ltd. (Trust account)	1,703,400	5.10
AVI JAPAN OPPORTUNITY TRUST PLC	1,620,800	4.85
THE BANK OF NEW YORK- JASDECTREATY ACCOUNT	1,362,000	4.08
The Dai-ichi Life Insurance Company, Limited	1,100,000	3.29
NAVF SELECT LLC	857,900	2.57
CACEIS BANK, LUXEMBOURG BRANCH/ AIF CLIENTS ASSETS	822,700	2.46
Nippon Life Insurance Company	799,200	2.39

*The Company owns 5,127,632 treasury shares, but these are not included in the above list of the ten largest major shareholders. The shareholding ratios exclude treasury shares from the calculation.

Distribution of shares by type of holder



Change in share price

